A Comparative study of Plasma Fibrinogen in Male and Female patients with Coronary Artery Disease by Sountharya, N
1 
 
A COMPARATIVE STUDY OF PLASMA FIBRINOGEN IN MALE AND 
FEMALE PATIENTS WITH CORONARY ARTERY DISEASE 
Dissertation submitted to 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI. 
In partial fulfillment of the regulations for the award of the degree of 
 
DOCTOR OF MEDICINE 
BRANCH I – M.D., GENERAL MEDICINE 
APRIL 2016 
 
DEPARTMENT OF MEDICINE 
TIRUNELVELI MEDICAL COLLEGE & HOSPITAL 
TIRUNELVELI 627011, TAMILNADU 
2 
 
CERTIFICATE 
 
This is to certify that the dissertation entitled “A COMPARATIVE STUDY OF 
PLASMA FIBRINOGEN IN MALE AND FEMALE PATIENTS WITH 
CORONARY ARTERY DISEASE” submitted by Dr.N.SOUNTHARYA to the 
Tamil Nadu Dr. M.G.R. Medical University, Chennai, in partial fulfilment of the 
requirement for the award of M.D. degree Branch I (General Medicine) is a 
bonafide research work carried out by her under my strict supervision and 
guidance. This dissertation partially or fully has not been submitted for any other 
degree or diploma of this university or other.  
  
Prof. Dr.M.R.VAIRAMUTHURAJU M.D. 
Professor and HOD, 
Department of Medicine, 
Tirunelveli Medical College, 
Tirunelveli. 
 
 
The Dean, 
Tirunelveli Medical College, 
Tirunelveli. 
3 
 
 
4 
 
 
 
 
5 
 
DECLARATION 
 
I, DR. N.SOUNTHARYA, solemnly declare that this dissertation entitled, “A 
COMPARATIVE STUDY OF PLASMA FIBRINOGEN IN MALE AND 
FEMALE  PATIENTS WITH CORONARY ARTERY DISEASE”  is a 
bonafide work done by me at Tirunelveli Medical College Hospital from August 
2014 to August 2015 under the supervision and guidance of my unit Chief, H.O.D 
of General Medicine,  Prof. Dr.M.R.VAIRAMUTHU RAJU M.D.,  
 
This dissertation is submitted to the Tamil Nadu Dr. M.G.R. Medical University, in 
partial fulfilment of regulation for the award of M.D. degree in General Medicine. 
This dissertation partially or fully has not been submitted for any other degree or 
diploma of this university or other.  
 
 
PLACE: TIRUNELVELI     (DR.N.SOUNTHARYA) 
DATE:       POST GRADUATE 
        M.D. GENERAL MEDICINE 
TIRUNELVELI MEDICAL 
 COLLEGE HOSPITAL. 
 
6 
 
ACKNOWLEDGEMENTS 
 
I take immense pleasure in acknowledging all those who helped me to make this 
dissertation a reality. 
 
I wish to express my gratitude to Dr. K. SITHY ATHIYA MUNAVARAH, 
M.D., Dean, Tirunelveli Medical College Hospital for allowing me to avail the 
facilities needed for the study.  
 
With the deep sense of indebtedness and reverence, I thank  
Dr. M. R. VAIRAMUTHU RAJU M.D., Professor and Head of the department 
of Internal Medicine for permitting me to do the study and for his support and 
encouragement throughout the study.  
 
I express my gratitude to Professor and HOD of Cardiology,  
Dr. RAVICHANDRAN  EDWIN MD., D.M., who allowed me to carry out this 
study in the Cardiology department and for his constant encouragement and 
scholarly guidance. 
 
 
7 
 
I would like to express my sincere gratitude to my Assistant Professors  
Dr. MOHAMMED RAFI M.D., and Dr. A. RAVI M.D., and Dr. P. RENUGA 
M.D., for their constant support and guidance.  
 
I also thank the department of Biochemistry and Pathology for offering me the 
laboratory support needed for this study.  
 
No Words of Gratitude will be enough to thank my family members for their 
unconditional support and encouragement at each step of this study. 
 
Last but not the least, my sincere thanks to all the patients who co-operated for this 
study without whom this study could not have been undertaken and to all my 
colleagues who helped me and shared their knowledge about the study. 
 
 
 
 
 
 
 
8 
 
ABSTRACT 
 
TITLE              
A COMPARATIVE STUDY OF PLASMA FIBRINOGEN IN MALE AND 
FEMALE PATIENTS WITH CORONARY ARTERY DISEASE 
 
BACKGROUND  
Coronary artery disease is the largest killer in developed countries and is rapidly 
becoming one in developing countries. Conventional risk factors do not explain all 
cases of coronary artery disease. The increasing risk of coronary artery disease 
among young suggests the possible role of non-conventional risk factors. 
 
In recent years, the role of plasma fibrinogen as an independent cardiovascular risk 
factor has been increasingly recognized. Thrombosis, endothelial dysfunction and 
inflammation are recognized as mechanism of atherosclerotic complications. 
Fibrinogen is a major determinant of fibrin formation, blood viscosity and platelet 
aggregation and thus enhances the thrombogenic tendency. 
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There is paucity of data on the emerging risk factors for coronary artery disease in 
Indian population especially women. Hence this present study is undertaken to 
evaluate the association of plasma fibrinogen in coronary artery disease patients. 
 
OBJECTIVE  
To estimate the level of plasma fibrinogen in both male and female patients 
presenting with acute myocardial infarction and to assess the association between 
plasma fibrinogen and coronary artery disease and compare between male and 
female patients. 
 
MATERIALS AND METHODS 
 
SOURCE OF DATA 
 Cases for the present study were selected randomly from the inpatients of 
ICCU ward, and male and female medical wards admitted with acute 
myocardial infarction, in Tirunelveli medical college hospital, Tirunelveli. 
 
PERIOD OF STUDY 
 August 2014 to August 2015 
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STUDY DESIGN 
 Prospective cross sectional study. 
 
SAMPLE SIZE 
 70 patients, 35 Males and 35 Females 
 
METHOD OF STUDY 
An informed consent taken from all subjects of the study. A detailed clinical 
history was taken and a thorough clinical examination and the required laboratory 
investigations were done. CPK-MB, Troponin-T, ECG, Plasma fibrinogen were 
taken in all subjects. 
The details collected from each patient was entered in the proforma. The data were 
analyzed and the results were compared.  
 
RESULT 
In this study of 70 patients involving 35 males, 35 females it was found that 
plasma fibrinogen levels were high in both male and female patients with coronary 
artery disease and the association was found to be statistically significant.  
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CONCLUSION 
The findings from our study provide evidence that plasma fibrinogen is associated 
with excess risk of CAD in women. But, the association between plasma 
fibrinogen and cardiovascular risk does not establish a cause-effect relationship. 
Further large scale studies are needed to establish the causal relationship of 
fibrinogen to coronary artery disease in both the sexes. 
 
KEY WORDS: Coronary Artery Disease, Plasma Fibrinogen, Female 
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INTRODUCTION 
 
Cardiovascular diseases (CVD) primarily Coronary Artery Disease (CAD) lead the 
top10 causes of deaths worldwide. It is estimated that one in every two deaths is 
due to CAD. 17.3 million Deaths were recorded so far. The developing countries, 
contributes to over 80% of these deaths. One prediction says that by the year 2030, 
around 23.6 million people will die from cardiovascular diseases (CVD).  
 
Women from the developing countries play a key role in managing the family 
health. Statistics reveal that 8 out of 10 women are affected by cardio vascular 
disease. Each year 8.6 million women around the globe die because of 
cardiovascular disease (CVD). This number is greater than the people who die 
from all cancers, tuberculosis, HIV/AIDS and other diseases. Around 3.3 million 
women die because of Myocardial Infarction, 3.2 million women die because of 
stroke and 2.1 million women die because of heart failure, hypertensive heart 
disease, inflammatory heart disease, and other CVDs. 
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The following image shows the total number of deaths due to cardio vascular 
disease worldwide. 
 
After the 1980s, gender specific trends became evident in these statistics: whereas 
death due to CAD decreased among men, there is a continuous rise in rates of 
death from CAD in women. 
 
This difference is due to the fact that CAD was considered a ‘male disease’, and 
that studies and research concentrated primarily on men. Hence in men, this 
phenomenon, in addition to improved modern medicine over the past 30 to 40 
years with its therapeutic approaches and preventive measures, have led to a 
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decrease in death rate. The contrary situation in females is due to two factors: that 
results obtained from research for men are not applicable to women, and/or that 
women do not enjoy all the advances in diagnosis and therapy. 
 
Moreover, after the 1980s, changes have taken place in the risk factor profile in 
both women and men. We know today that there are a number of gender specific 
differences in the development, course, symptom complexes, diagnosis, therapy, 
and prognosis of CHD. In women, CHD occurs about 10 to 15 years later than in 
men. Risks drastically increase after menopause, due to decrease of endogenous 
sexual hormones, especially oestrogens. 
 
Though women are also exposed to the same atherogenic risk factors as men, the 
significance and the relative weighting of these factors are different. The reasons 
for these differences are presently unclear. However, enhanced insights into the 
differences between male and female atherogenic risk factors are essential towards 
achieving optimal gender-specific disease prevention and therapy. 
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Inflammation plays an important role in the pathogenesis of atherosclerosis. 
Studies have shown that markers of inflammation are independent predictors of 
cardiovascular events. Clinical studies in patients with acute coronary syndromes 
found highly increased levels of inflammatory markers.  
 
Numerous studies have confirmed Fibrinogen as a major independent risk factor 
for cardiovascular diseases. Fibrinogen has also been associated with traditional 
cardiovascular risk factors, suggesting that the elevation of fibrinogen may be a 
pathway by which these risk factors exert their effect. There are several 
mechanisms by which fibrinogen may increase cardiovascular risk. 
 
1. It binds specifically to activated platelets via glycoprotein IIb/IIIa, 
contributing to platelet aggregation. 
2. Increased fibrinogen levels promote fibrin formation. 
3. It is a major contributor to plasma viscosity.  
4. It is an acute-phase reactant that is increased in inflammatory states. 
 
The association between high fibrinogen concentrations and the risk of 
cardiovascular disease was first reported in the Northwick Park Heart Study in 
1980's. Numerous other prospective studies have confirmed a strong and 
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independent effect of raised plasma fibrinogen on both the onset and the 
progression of ischaemic heart disease (IHD), stroke and lower extremity arterial 
disease. The strength of the association is similar to that of cholesterol or blood 
pressure. Thus, men with plasma fibrinogen concentrations in the upper third of its 
distribution experience between 2.0 and 2.5 times the incidence of IHD compared 
with those with values in the lower third. 
 
Further, data from the Framingham Heart Study support and also characterize the 
association between fibrinogen and cardiovascular disease. First, increased 
fibrinogen may be a pathway by which the traditional risk factors exert their effect 
on risk. Second, fibrinogen levels are higher among subjects with prevalent 
cardiovascular disease. These findings, together with other prospective studies 
identifying fibrinogen as an independent risk factor, add strength to the proposal 
that Plasma fibrinogen measurement can assist in the risk stratification of patients 
at risk of cardiovascular disease. 
 
The Framingham Heart study has also confirmed this relation in women. But apart 
from this study, the possible relation between plasma fibrinogen and cardio 
vascular risk in women has been less investigated. 
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AIMS OF THE STUDY 
 
 
 To estimate the plasma fibrinogen level in subjects with acute myocardial 
infarction.  
 
 To assess the association between plasma fibrinogen and coronary artery 
disease and compare it between male and female patients. 
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REVIEW OF LITERATURE 
 
India has the most valuable asset, young population. It is now under threat due to 
rapidly increasing cardiovascular disease (CVD). Indians are more prone to 
coronary artery disease but conventional risk factors do not explain the high rates 
of Coronary Artery Disease among Indians. Myocardial infarction is claiming a 
large number of lives in India. An impressive difference was absence of traditional 
risk factors in a third of them. Novel risk factors like homocysteine, lipoprotein (a), 
small LDL particle and fibrinogen may play a significant role in these patients. 
 
One statistics report in India says that myocardial infarction kills 4 people every  
minute of age between 30 and 50. Around 1000 people of age 30-40 dies due to 
myocardial infarction every day in India. Word Health organization (WHO) reports 
says that around 6.3K Indians of age around 35-40, diagnosed with cardiovascular 
disease (CVD) every day.  
 
 Many women die every year from cardiovascular disease than from any other 
cause, yet women worry more about breast cancer than heart disease. Women with 
heart disease may present differently than men, have unique underlying 
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pathophysiologies, and have distinctive risk benefit profiles with commonly 
accepted therapies.  
 
Heart disease is far more age dependent in women than in men; women with 
cardiovascular disease are older and have more co morbidities. This fact, in turn, 
make diagnostic and treatment procedures more problematic in women. In 
addition, many effective pharmacological strategies are underutilized, and there is 
a lack of gender-specific date on numerous therapies. The fact that heart disease is 
on the decline in men but not women highlights our failure to treat this large 
segment of the population optimally. 
 
The aetiology of atherothrombotic cardiovascular disease is multi-factorial, and 
several ‘risk factors’ are recognized to predispose an individual to develop the 
disease. 
 
These cardiovascular risk factors, which were initially characterized in the 
Framingham Heart Study, include: age, family history of premature cardiovascular 
disease, smoking, hypertension, hyperlipidaemia, diabetes, obesity and sedentary 
lifestyle. 
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Although a family history of cardiovascular disease is a recognized risk factor, it is               
important to emphasize that cardiovascular disease is polygenic and numerous 
genetic abnormalities have been implicated in the development of the final 
common disease state. Furthermore, expression of disease is often closely linked to 
environmental risk factors such as smoking, diet and physical inactivity  
 
Clearly, therefore, the ‘burden of disease’ in a population is strongly associated 
with the prevalence of recognized risk factors within that population. Incidence 
and prevalence rates for cardiovascular diseases depend to a large extent on the 
age profile of the population, socio-economic, dietary and other lifestyle patterns; 
although other influences, including genetic differences influenced by ethnicity, 
are also important. 
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Cardiovascular Disease (CVD)  
The following chart shows the cardiovascular disease (CVD) that involve blood 
vessels.  
CARDIOVASCUALR DISEASE (CVD) WITH BLOOD VESSELS 
INVOLVEMENT.
 
 
 
 
 
Coronary artery 
disease
Peripheral arterial 
disease
Cerebrovascular 
disease
Renal artery stenosis Aortic aneurysm
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The following chart shows the cardiovascular disease (CVD) that involve heart. 
CARDIOVASCUALR DISEASE (CVD) WITH HEART INVOLVEMENT. 
 
 
The following diseases are falls under cardiovascular disease (CVD) category, they 
are Coronary artery diseases (CAD) that includes Angina and Myocardial 
Infarction, Stroke, Hypertensive heart disease, Rheumatic heart disease, 
Cardiomyopathy, Atrial fibrillation, Congenital heart disease, Endocarditis, Aortic 
aneurysms, Peripheral artery disease and Venous thrombosis.  
 
Cardiomyopathy Valvular heart disease
Congenital heart 
disease
Rheumatic heart 
disease
Hypertensive heart 
disease Heart failure
Pulmonary heart 
disease
Cardiac 
dysrhythmias
Inflammatory heart 
disease
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CORONARY ARTERY DIESEASE (CAD):  
Every day about 3,000 gallons of blood through vessels are pumped by a strong 
muscular pump, the human heart. Our heart requires a continuous flow of blood 
supply to function properly. Coronary artery is responsible for feeding the blood to 
the heart muscles.  
 
The other names for Coronary artery disease (CAD), are ischemic heart disease 
(IHD), atherosclerotic heart disease, atherosclerotic cardiovascular disease, and 
coronary heart disease, which includes, stable angina, unstable angina, myocardial 
infarction, and sudden coronary death. Coronary artery disease (CAD) is one 
among the diseases in the cardiovascular disease (CVD), but it is the most common 
disease among them. Symptoms which are common for Coronary artery Disease 
(CAD) are chest pain or discomfort in the shoulder, arm, back, neck, or jaw. 
Heartburn will come occasionally. 
The World Health Organization (WHO) definition includes the presence of two of 
the following 
1. Symptoms of myocardial infarction 
2. Cardiac markers (enzymes) elevated 
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3. ECG showing characteristic electrocardiographic changes 
 
Newer diagnostic criteria according to the American College of Cardiology and 
European Society of Cardiology. It requires the presence of one of the following 
diagnostic criteria to satisfy the diagnosis of acute, evolving or recent myocardial 
infarction. 
1. Typical rise and gradual fall (troponin I/T) or more rapid rise and fall (CK-MBs) 
of biochemical markers of cardiac muscle necrosis with any one of the following: 
a. Symptoms of myocardial ischemia 
b. Appearance of pathological Q waves in ECG 
c. ECG changes suggestive of ischemia (ST segment elevation / depression) 
d. Coronary artery intervention (Eg. Coronary angioplasty) 
2. Pathological findings of an acute Myocardial infarction 
Atherosclerosis is a condition by which an artery wall thickens as a result of 
invasion and accumulation of white blood cells (WBCs) (foam cell) and 
proliferation of intimal smooth muscle cell creating a fibrofatty plaque. 
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The plaque deposits contain both living, active WBCs which causes inflammation, 
cholesterol and triglycerides. The remnants eventually include calcium and other 
crystallized materials within the outermost and oldest plaque. This plaque deposit 
reduce the elasticity of the artery walls. This process won’t stop the blood flow for 
years, because blood vessels will adjust themselves at the area of plaque deposits. 
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The stiffening of wall may increase pulse pressure; widened pulse pressure is one 
possible result of advanced disease within the major arteries. 
 
The plaque deposits on the artery walls is due to a chronic inflammatory response 
of WBCs. Low-density lipoproteins (LDL, plasma proteins that carry cholesterol 
and triglycerides) initiates this process, without adequate removal of fats and 
cholesterol from the macrophages by functional high-density lipoproteins (HDL). 
It is commonly referred to as a "hardening" or furring of the arteries. It is caused 
by the formation of multiple atheromatous plaques within the arteries. 
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The plaque is isolated into three varied components: 
 The atheroma, which is the nodular accumulation of a soft, flaky, yellowish 
material at the center of large plaques, composed of macrophages nearest the 
lumen of the artery. 
 Bottom area of cholesterol crystals. 
 Calcium (Ca) deposit at the outer area of the older or more advanced lesions 
(Tissue with some abnormalities). 
 
Risk factors 
American heart association (AHA) on the conference held in the year 1999, they 
classified the risk factors into 3 categories. Those are given below.  
 
1. Traditional /Conventional risk factors. 
 Smoking, 
 Low in HDL cholesterol 
 Elevated serum cholesterol 
 Hypertension 
 Diabetes mellitus 
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2. Predisposing factors 
 Gender 
 Physical inactivity 
 Family history of CAHD 
 Overweight & obesity 
 Insulin resistance 
 
3. Conditional factors 
 Homocysteine 
 Fibrinogen 
 Small LDL particle 
 C-reactive protein 
 Lipoprotein (a) 
 
Emerging risk factors 
 Nitrotyrosine 
 Oxidative stress 
 Asymmetric dimethylarginine 
 Myeloperoxidase 
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Smoking 
Use of tobacco in the form of smoking is falls under the risk factor category that 
can be changeable/modifiable. This will also initiates other risk factors to come in 
lime light. Smoking will increases the risk of coronary atherosclerosis in men and 
women, irrespective of all ages. Smoking increases the risk of thrombosis (Blood 
clot formed inside a blood vessel, obstructing the flow of blood through the 
circulatory system), plaque rupture (Atheroma becomes vulnerable when the 
growth is rapid and it creates a thin cover that separates from the bloodstream 
inside the arterial lumen.), myocardial infarction (Heart Attack), Arrhythmias 
(heartbeat is irregular, too fast, or too slow.)  And sudden death. 
 
Smoking will initiates the oxygen (O2) demand of myocardial tissue and hence 
making angina. Usage of tobacco in the form of smoking is responsible for 40% of 
Coronary artery disease (CAD). Even the passive smokers about 8% is also 
affected by Coronary artery disease (CAD).  
 
Consumption of all tobacco products increases the risks for Coronary artery 
disease (CAD). Tobacco usage makes the blood vessels to lose the elasticity and 
make them hard. This results in blood clot or blocks the blood flow through 
coronary artery.  
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There is a misconception that occasional smokers are not at risk. If a person quits 
smoking, it will take three years for the body and heart to recover from the effects 
of tobacco. It has been found that 28% of all deaths from coronary heart disease 
are attributed to tobacco smoking. Compared with non-smokers, current smokers 
have a 70% increased risk of fatal coronary event and a two to four fold increased 
risk of non-fatal CAD. 
 
Hyperlipidemia 
Fats in the blood is termed as Lipid. Proper levels of lipid perform important 
functions in our body, but can cause health problems if they are present in excess. 
Hyperlipidemia (High lipid levels) means that high cholesterol and high 
triglyceride levels deposit. Hyperlipidemia causes the arteries to lose their 
elasticity. 
 
Atherosclerosis increases your risk of heart disease, stroke, and other vascular 
diseases. Fortunately, you may be able to reduce high lipid levels and, therefore, 
prevent or slow the progression of atherosclerosis. Lifestyle changes like 
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exercising and eating a healthy diet can also lower your lipid levels and are often 
the first step in treatment. 
 
Hypertension 
In the modern word fast food is now inevitable and hence consumption of salt has 
been increased in the recent years. Stress also causes hypertension. Due to change 
of food habits we are consuming more trans-fat. People with high blood pressure 
are likely to develop Coronary artery disease (CAD) because high BP places an 
added force on the artery walls and over time, the extra pressure can damage the 
arteries. These injured arteries are most likely to become narrowed and hardened 
by fatty deposits. 
 
Diabetes mellitus 
Due to change of diet, young people are getting diabetes. The rise in diabetes is 
one among the risk factors for Coronary artery disease (CAD). Due to diabetes, a 
large portion of the heart will be damaged. Treatment for sudden cardiac diseases, 
also responds very poorly. 
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Diabetes will form the multiple blood clots often (Like Smoking), which will block 
the oxygen (O2 ) and vital minerals supply to brain and heart. 
 
The coronary artery disease (CAD) is responsible for 75% of all deaths in diabetic 
patients. There is endothelial and smooth muscle function impairment in diabetic 
patients. They also have increased adhesion of leukocytes to the vascular 
endothelial surface. This is very important step in atherosclerosis. 
 
Patients with diabetes mellitus have two to eight fold higher rates of future 
cardiovascular events as compared with age and ethnically matched non-diabetic 
individuals. 
 
Gender 
Men have increased risk of atherosclerosis than pre menopause women. It is the 
most important predisposing factor for coronary atherogenesis. The female sex is 
having a protection from coronary artery disease by estrogen. Post menopause 
females are having equal risk of coronary artery disease (CAD) like men.  
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Obesity 
In Modern India, people are having unity in diversity in Obesity. India is divided 
by not only by states and languages but also by over nourished and the 
malnourished. 
 
Obesity is the key reason to develop diabetes, high BP, high cholesterol. In India 
people stores fats in the form ‘apple type,’ which is dangerous because of all 
metabolic byproducts of visceral fat cells easily enter the liver and get stored as fat. 
 
Unhealthy food habits 
Due to modernization, Indian vegetarian food is also equally dangerous to Non-
Vegetarian food. Since Indians used to consume more refined carbohydrate, 
saturated fat, trans-fat and fried items in their diet. Today youngsters are highly 
attracted towards junk food, causing obesity in the early ages.  
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Physical inactivity 
Technology makes a rocket science easier but physical activities harder to handle. 
Physical inactivity initiates the other risk factors for Coronary artery disease 
(CAD), such as hypertension, diabetes and obesity. 
 
In the world youngster population around 80 % of people are physically inactive 
and remaining 20% concentrates only on muscle development rather than aerobics. 
 
The American Heart Association has recommended an exercise energy expenditure 
approaching 2000 calories each week, a level of exercise that can be achieved with 
modest daily exertion. 
 
Novel atherosclerotic risk factors 
A bunch of new risk factors for atherothrombotic risk are identified. They are 
proved by epidemiological studies. They are useful clinically. They are fibrinogen, 
lipoprotein (a), plasminogen activation inhibitor-1, homocysteine and high 
sensitivity C reactive protein. 
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C reactive protein 
C reactive protein is a pentraxin family member and plays an important role in the 
human innate response. This will also affects vascular vulnerability. If test value of 
CRP > 3 mg/L then there may be the chance for recurrent coronary events. 
 
Lipoprotein (a) 
Berg et al first described in detail, followed by Mclean et al who describes about it 
clinical importance. There are some structural similarities with apoprotien (a) and 
plasminogen. 
 
It has LDL particle with apo B-100. This component is linked by a disulphide 
bridge to apoprotien (a). One of the member of the family ‘KRINGLE’, 
Apoprotien (a) is containing proteins. Other members of this family include 
proteins such as Plasminogen, Prothrombin, Factor XII, urokinase type 
Plasminogen activator and Macrophage stimulating factor. 
 
Lipoprotein (a) acts by binding on the endothelium. It competes with plasminogen. 
It binds to plasminogen receptor on endothelium. Thus it reduces the activity of 
plasminogen. Many epidemiological studies proves positive relation between 
lipoprotein (a) and atherogenic risk. 
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Their plasma concentration is inversely proportional to the size of apoprotein 
isoform. Thus small isoforms are associated with higher plasma Lp(a) 
concentration. 
At birth Lp (a) levels are low and adult levels achieved in two years. Levels are 
high in asian and African population. Levels above 30 mg/dl are significant. 
 
Serum Lp(a) levels elevated in type 2 DM, renal failure, menopause , 
hypothyroidism and malignancy. Height, weight, BMI, diet, weight loss and 
physical activity do not affect the level of serum lipoprotein (a). 
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FIBRINOGEN 
Fibrinogen, is one among 13 coagulation factors that is responsible for normal 
blood clot. Fibrinogen is called as Factor 1(I), which is a blood plasma protein. 
Many studies about fibrinogen confirms that plasma fibrinogen is key risk factor 
for cardiovascular disease (CVD). When the blood starts bleeding then our body 
initiates coagulation cascade, which is the process by which blood separates the 
plasma to form a thick mesh and to stop bleeding. If plasma fibrinogen is 
insufficient or the cascade is not working, that results in excessive bleeding, will 
cause fatal results. 
 
When the level of plasma fibrinogen is low than the required value 150-400 mg/dl 
then there will be the possibilities of thrombosis. Thrombosis is the process of 
forming a clot inside blood vessel. The clot bocks the normal flow of blood 
through the circulatory system. This can lead to serious medical conditions such as 
heart attack and stroke. 
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FIBRINOGEN STRUCTURE: 
 
Plasma fibrinogen is synthesized in the liver by the hepatocytes. It is released into 
circulation with half-life of nearly 100 hrs. It is degraded at rate of 24 % per day. 
The turnover rate of fibrinogen is about 1.7 to 5.0 gm/day. 
 
 
 
The fibrinogen, a precursor of fibrin with molecular weight of 340 kDa, with 
length 45 nm, diameter 9nm, is a glycoprotein molecule. Normal plasma level is 
200 to 400n mg / dL. It consists of three pairs of polypeptide chains (3X2). They 
are namely Aalpha(Aα), Bbeta & gamma chains. They are held together by 29 
disulphide bonds. There are 2 Aalpha, 2 Bbeta and 2 Gama chains. 
 
 
The central nodule or E-domain is 5 nm in diameter and contains the NH2-terminal 
of all six polypeptide chains forming the NH2-terminal disulfide knot. The two 
outer D-domain nodules are composed of the C-terminal two thirds of both the Bβ 
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and γ chains. Between the E- and D-domains, there is a stretch of approximately 
120 amino acids from each of the three chains that forms an α-helical structure 
known as the coiled-coil domain. This region of the molecule is supported on both 
sides by a set of disulfide bonds called disulfide rings. These rings play an 
important role in making fibrin mechanically strong and resistant to proteolysis. 
Structural elements in each of the individual chains are needed for blood 
coagulation. 
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Fibrinogen alpha chain 
Gene-Phenotype Relationships in alpha chain 
 
 
 
The alpha component of fibrinogen composed of 3 pairs of non-identical chains 
made of polypeptide. During vascular damage, fibrin will be formed from 
fibrinogen by thrombin, which is the most ample component of blood clots. Cell 
adhesion and spreading is controlled by numerous products of fibrinogen and 
fibrin. Display vasoconstrictor and chemotactic activities, and are mitogens for 
several cell types. Many disorders like dysfibrinogenemia, hypofibrinogenemia, 
afibrinogenemia, and renal amyloidosis are created by mutating the alpha gene. 
Alternative splicing results in two isoforms that vary in the carboxy-terminus. The 
3 pairs of plasma fibrinogen are located on chromosome 4.  
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The identifiers for fibrinogen alpha chain is as below. 
 
 
 
After nerve crush, fibrin is deposited and the cleaning is interconnected with repair 
of nerve after injury of nerve. A thorough study shows that quantitative 
myelinating axons are more in fibrinogen-deficient than the normal one. Fibrin 
induced ERK1 (MAPK3; 601795)/ERK2 (MAPK1; 176948) and production of 
p75 nerve growth factor low-affinity receptor (NGFR; 162010) in Schwann cells; 
Both ERK1 and NGFR  are maintained in a nonmyelinating state  by fibrin, 
suppressed fibronectin production, and prevented synthesis of myelin proteins.  
 
 
There is a conjectured study that says, regulation of fibrin clearance and/or 
deposition is a regulatory mechanism for Schwann cell differentiation after nerve 
damage.  Apart from Cardiovascular disease (CVD), fibrinogen is also a 
cerebrovascular risk factor in Alzheimer disease that will alter fibrin clot structure 
and causing delay in clot degradation. RU-505 act as an inhibitor of the interaction 
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between beta-amyloid and fibrinogen. The interaction between beta-amyloid and 
fibrinogen may be useful in AD therapy.   
 
Fibrinogen beta chain 
 
Gene-Phenotype Relationships in beta chain 
 
 
 
 
To bind vascular endothelial cadherin both FGB (15-42) peptide fragment and 
fibrin fragment N-terminal disulfide knot-II are used. So this bind will stop 
transmigration of leukocytes across endothelial cell monolayers. Interplay of fibrin 
fragments, leukocytes, and CDH5 contributes to the pathogenesis of myocardial 
damage and reperfusion injury. 
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The identifiers for fibrinogen beta chain is as below. 
 
 
 
 
A detailed study says that fibrinogen genes RFLPs is having a strong association 
between polymorphism detected with a beta-fibrinogen probe and the enzyme BclI. 
About 15% of variance was recorded for fibrinogen locus out of total variance in 
fibrinogen level. 
 
In a large study, found that the -455G-A polymorphism in the FGB promoter is 
associated with an increase in plasma fibrinogen in both genders, but does not 
appear to cause ischemic heart disease. 
 
There is a relationship between FGB locus which is present in homozygous or 
heterozygous state of an allele. Mutation in the FGB gene will cause 
dysbetafibrinogenemia with thrombosis, and congenital afibrinogenemia. 
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Truncation of the 7 most C-terminal residues (arg455 to g1n461) of the B-beta 
chain specifically inhibited fibrinogen secretion. Expression of additional mutants 
and structural modeling suggested that neither the last 6 residues nor arg455 is 
crucial per se for secretion, but prevents protein misfoldine by protecting 
hydrophobic residues in the B-beta C-terminal core. Immunofluorescence and 
immunoelectron microscopy studies indicated that secretion-impaired mutants 
were retained in a pre-Golgi compartment. In addition, expression of FGB, FGG, 
and angiopoietin-2 (ANGPT2; 601922) chimeric molecules demonstrated that the 
B-beta C-terminal domain prevented the secretion of single chains and complexes, 
whereas the gamma C-terminal domain allowed their secretion. 
 
In a study of 23,634 European Americans and 6,657 African American participants 
they identified a rare pro265-to-leu variant in FGB (rs6054) associated with lower 
fibrinogen. 
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Fibrinogen alpha/beta chain family 
 
 
 
Fibrinogen gamma chain 
 
Gene-Phenotype Relationships in beta chain 
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In the study of single fibrin fibers using an atomic force-fluorescence microscopy 
technique. They determined the extensibility and elastic limit of fibers formed in 
the presence and absence of factor XIIIa. Factor XIlla induces covalent crosslinks 
between gamma chains (along the fiber axis) and between the alpha chains. 
Samples without factor XIIIa showed no crosslinking. Uncrosslinked fibers 
extended 226 +/- 52%, and crosslinked fibers extended 332 +/- 71%, or 4.32 times 
their original length. The most extreme fibers could be extended over 6 times their 
length. These extensibilities are the largest of any protein fiber. These data 
suggested that clot rupture does not arise from the rupture of individual fibers, as 
had been assumed; rather, the branch points of the network forming the clot yield 
first. 
 
The identifiers for fibrinogen gama chain is as below. 
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Fibrinogen gamma chain 
 
 
 
Function 
 
It is the clotting factor I, according to the system for naming blood clotting factors.  
It plays vital role in coagulation pathway. It produces fibrin on activation. 
  
Results in fibrin which binds to lipoprotein and LDL and retains lipid moiety in the 
plaque. It is also important mediator in inflammation and atherogenesis. It plays 
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pivotal role in throinbogenesis. The possible mechanisms include increased blood 
viscosity and enhanced platelet aggregation. It also causes atherothrombosis by 
infiltrating the vessel wall. Thus they favour thrombus formation. 
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Role in Inflammation 
 
They interact with WBCs by `integrins'.The integrins are surface receptors coated 
on the leukocytes.Macl and alpha X and beta 2 are the fibrinogen binding 
receptors.Mac 1 is very specific for fibrinogen. Fibrinogen also bind with 
intercellular adhesion molecule-1 (ICAM-1L ICAM-1 is otherwise called CD54.It 
is present over vascular endothelium. 
 
Fibrinogen attaches with Macl and also interacts with ICAM-1 to cause adhesion 
of monocytes over vascular endothelium. Fibrinogen also upregulates the 
expression of ICAM-1 or CD54 over the vascular endothelium.  
 
Fibrinogen favours chemotaxis. Thus it is important in inflammation. This effect is 
mediated by binding with integrins receptors of leukocytes. As a consequence of 
this activation.the neutrophil activation markers are expressed. There is also 
increase in calcium concentration intracellularly. Fibrinogen favors cell to cell 
adhesion and also facilitate cell to collagen (extracellular matrix). Thus it 
facilitates the inflammatory response. 
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Role in Thrombogenesis 
Thrombogenesis is regulated by a fine balance between the coagulation and 
fibrinolytic pathways Subsequent to vessel wall trauma, tissue thromboplastin is 
released from the sub-endothelium. Tissue thromboplastin in turn triggers the 
extrinsic pathway of coagulation by activating factor VII to Vida. Contact of blood 
with the foreign surface initiates the intrinsic pathway of coagulation, by activating 
factor XII to XIIa, as well as platelets. Platelet aggregation, however, does not 
confer adequate stability, and therefore activation of the coagulation pathway is 
also necessary. 
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Role in Atherogenesis 
Fibrinogen plays pivotal role in causing endothelial damage. The fibrin formed 
upon activation of fibrinogen, initially acts over the intimal layer of the vessel wall 
and it promotes cellular proliferation. They favour cell migration and cell adhesion. 
The fibrin degradation products are the main stimuli for chemotaxis, extracellular 
matrix synthesis and their proliferation. This affects the vascular permeability and 
their tone. There is clear evidence for large amount of fibrin deposition in the 
atherosclerotic lesions in the human blood vessels. They are present either over the 
intact surface of plaque or buried within the fibrous cap. 
 
Determinants of fibrinogen 
 
Genetics:  
There is 30 to 50 % variation in the genetic polymorphism  
 
Gender:  
The post-menopausal women generally have their fibrinogen levels elevated when 
compared with age matched men. This is irrespective of pregnancy. It is also 
independent of use of oral contraceptive pills. 
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Smoking:  
Smoking increases the risk of elevation of fibrinogen. There is proportional 
increase of 350mg/dl with each cigarette smoked. Smoking causes inflammation of 
pulmonary alveoli and bronchus. This in turn increases concentration of IL-6 
which promotes synthesis of acute phase reactants from liver. 
 
Alcohol:  
Moderate alcohol consumption reduces plasma fibrinogen levels. According to 
DESIR study, those who do not take alcohol or heavy drinkers taking more than 
70gms/day have more plasma fibrinogen values. 
 
Obesity:  
BMI, Waist Hip Ratio (WHP), and Waist circumference in both male and female is 
having a positive relationship with obesity, increasing the risk of elevated plasma 
fibrinogen levels. 
 
Exercise:  
Regular physical inactivity increases the level of fibrinogen. The people having 
more physical activities, having low fibrinogen levels. This effect attributes to the 
cardiovascular benefits of regular physical exercise. 
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Hormonal Influence:  
The use of oral contraceptive pills is associated with elevated fibrinogen levels 
 
Age:  
Age contributes to increased fibrinogen levels. This is attributed to the delayed 
clearance from plasma. 
 
Role of Vitamins:  
Dietary intake of Vitamin C reduces plasma fibrinogen to a great extent. 
 
Role of Infections:  
Certain organisms like Helicobacter pylori and Chlamydia were implicated in 
causing coronary artery disease. The role of fibrinogen may be explained following 
these infections. Its level is also increased in periodontal infections. 
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Fibrinogen Assays 
Assays 
 
Clauss A functional assay based upon the time 
for fibrin clot formation 
PT-derived Fibrinogen Assays A derived fibrinogen based upon the 
prothrombin time 
Immunological An immunological method which 
measures fibrinogen antigen rather 
than functional fibrinogen 
Gravimetric A method based upon clot weight 
 
 
Methods: 
 
Assay 
Clauss Assay Diluted plasma is clotted with a high concentration of 
thrombin. The plasma is diluted (usually 1:10 but this may vary 
if the fibrinogen concentration is very low or very high) to 
minimise the effect of 'inhibitory substances' within the plasma 
e.g. heparin, elevated levels of FDPs. 
The use of a high concentration of thrombin (typically 100 
U/ml) ensures that the clotting times are independent of 
thrombin concentration over a wide range of fibrinogen levels.  
 
The test requires a reference plasma with a known level of 
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fibrinogen calibrated against a known international standard. A 
calibration curve is constructed using this reference plasma by 
preparing a series of dilutions (1:5 –1:40) in buffer to give a 
range of fibrinogen concentrations. The clotting time of each of 
these dilutions is established (using duplicate samples) and the 
results (clotting time(s)/fibrinogen concentration (g/L) are 
plotted on log-log graph paper. The 1:10 concentration is 
considered to be 100% i.e. normal. There should be a linear 
correlation between clotting times in the region of 10-50s.  
The test platelet poor diluted plasma (diluted 1:10 in buffer) is 
incubated at 37°C, phospholipid and thrombin are added 
followed by calcium (all pre-warmed to 37°C). On the addition 
of the calcium timing begins. The time taken for the clot to 
form is compared to a calibration curve and the fibrinogen 
concentration deduced.  
Most laboratories use an automated method in which clot 
formation is deemed to have occurred when the optical density 
of the mixture has exceeded a certain threshold. 
PT-derived 
Fibrinogen 
Assays 
The PT is determined by optical density change for a range of 
plasma dilutions with known fibrinogen levels. The optical 
change for each different fibrinogen level is plotted as a 
calibration curve. A PT is performed on the patient’s platelet 
poor plasma and the fibrinogen derived from the change in 
optical density compared to the calibration curve.  
The derived fibrinogen is a simple and inexpensive test and is 
widely used. However, the test can give misleading results in 
some disorders and is not recommended for routine laboratory 
use. 
Immunological 
Assays 
Assays based on enzyme linked immunoabsorbant assays 
(ELISA), radial immunodiffusion and electrophoresis are the 
most commonly employed. 
Immunological assays measure protein concentration rather 
than functional activity.   
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They are of value in the investigation of congenital 
dysfibrinogenaemias where there is a discrepancy between 
functional activity and antigen level.  
Gravimetric 
Assays 
1. Clot Weight 
Similar to the Clauss method - a fibrinogen clot is formed by 
the addition of thrombin and calcium to dilute patient plasma. 
However, instead of using the time to clot formation to derive 
the fibrinogen the clot is compressed (to extrude plasma and 
unused reagents), washed, dried then weighed. This assay is 
technically difficult and time consuming.  
 
 
2. Clottable protein 
Thrombin is added to plasma without calcium and the clot 
formed is washed then dissolved in an alkaline reagent then 
spectrophotometry is performed (e.g. typically absorbance at 
282nm). The clot is almost all fibrin and so the measured 
protein concentration is taken as equivalent to the fibrinogen 
concentration.  
TEG The thromboelastogram has been used to measure functional 
fibrinogen levels 
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Fibrinogen assay for different clinical circumstances 
 
 Assays 
 
Investigation of bleeding Clauss 
Suspected dysfibrinogenaemia Clauss and clottable protein and 
immunoassay 
Bleeding disorders affecting factors in 
addition to fibrinogen (e.g. DIC) 
Clauss 
Thrombolytic therapy Clauss 
Very high fibrinogen levels Clauss or immunoassay 
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MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
SOURCE OF DATA 
 Cases for the present study were selected randomly from the inpatients of 
ICCU ward, and male and female medical wards admitted with acute 
myocardial infarction, in Tirunelveli medical college hospital, Tirunelveli. 
 
PERIOD OF STUDY 
 August 2014 to August 2015 
 
STUDY DESIGN 
 Prospective cross sectional study. 
 
SAMPLE SIZE 
 70 patients, 35 Males and 35 Females 
 
METHODOLOGY 
All patients admitted to the Intensive Coronary Care Unit, male and female 
medical wards in whom a diagnosis of acute Myocardial Infarction was made 
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based on clinical features, ECG changes and elevated cardiac biomarkers, were 
considered for the study. 
 
Inclusion Criteria 
All patients of both the sexes admitted in ICCU and medicine wards are included 
in the study if  
 Patients fulfilling WHO criteria for acute myocardial infarction 
 At least two of the three elements presenting within 48 hours 
• History of ischemic chest discomfort 
• Typical ECG changes 
• Elevated cardiac enzymes 
 
Exclusion Criteria 
• Smokers 
• Patients with diabetes mellitus 
• Patients with CVA/ history of CVA 
• Patients with Peripheral vascular disease 
• Women on HRT 
• Women on OCP 
• Patients with evidence of infection/inflammation 
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• Patients on Fibrates, CCB, beta blockers 
• Patients with liver disease, renal disease, respiratory failure 
• Congenital Heart disease 
• Rheumatic Heart disease 
• Structural Heart disease 
• Electrical abnormalities 
 
Persons included in the study were informed about the aim of the study and 
consent (Annexure II) was obtained. The necessary clearances from the concerned 
departments and the ethical committee was obtained prior to the start of the study. 
 
A detailed clinical history was taken and a thorough clinical examination and the 
required laboratory investigations were done. The details collected from each 
patient was entered in the Proforma. (Annexure I). 
 
The details of the patients regarding age, sex, presenting symptoms, risk factors 
like smoking, alcohol intake, food habits, diabetes, hypertension, drug intake and 
menstrual status were recorded. The vital signs like Pulse and Blood pressure were 
recorded and Body mass index was calculated. 
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Patients were classified accordingly as overweight and obese based on body mass 
index.  
 
BMI = Weight (kg)/height (mt2)  
Obesity - BMI > 30  
Over weight - BMI 25 to 30 
 
All the patients were subjected to routine laboratory investigations like complete 
blood count, renal function tests, liver function test, random blood sugar and lipid 
profile.  
 
According to NCEP-ATP III guidelines, patients were considered to have 
dyslipidemia when 
• Total cholesterol > 200 mg%, 
• HDL < 40 mg% 
• LDL > 100 mg% 
• Triglycerides > 150 mg% 
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Serum Creatinine Phosphokinase MB (CPK-MB) were also measured. ECG was 
taken in all patients, Troponin-T levels was done in NSTEMI and unstable angina 
patients. 
 
Plasma fibrinogen level                          
The Plasma fibrinogen levels were measured quantitatively by Coagulation method 
done by SYSMEX 500 series. Plasma fibrinogen values greater than 400 mg/dl is 
considered as hyperfibrinogenemia. All the patients were followed up during their 
hospital stay and the outcome recorded. 
 
The information collected regarding all the selected cases were recorded in a 
Master Chart (Annexure III). Data analysis was done with the help of computer 
using a software  called Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta, USA. 
 
Using this software, all the range, frequencies, percentage, mean, standard 
deviation, chi square and p value can be calculated. The tests used are One way 
ANOVA test and Student’s‘t’ test for data and Kruskul Wallis Chi-square test for 
consolidated tables. 
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OBSERVATIONS AND RESULTS 
70 patients (including 35 Males and 35 Females) with clinical features and ECG 
features suggestive of myocardial infarction were enrolled in our study. Plasma 
Fibrinogen levels were measured in addition to other routine investigations and the 
results compared. 
AGE DISTRIBUTION 
In this study the average age of males were 56.05 and average age of females were 
64.17 
Table 1: Age wise distribution of cases in Males 
 
SL.NO AGE IN YEARS NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  35-45 4 11.43 
2.  45-55 15 42.86 
3.  55-65 9 25.71 
4.  65-75 7 20 
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Table 1 show male patients were between the age group of 35 to 75 years. There 
were 4 patients (11%) below 45yrs of age. Youngest male patient in this study was 
36 years old. 
 
Chart 1: Age wise distribution of cases in Males 
 
 
 
Chart 1 shows the age wise distribution of cases in males. In our study, MI was 
common in the age group of 45-55yrs among male patients. 
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Table 2: Age wise distribution of cases in Females 
 
SL.NO AGE IN YEARS NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  35-45 0 0 
2.  45-55 3 8.57 
3.  55-65 14 40 
4.  65-75 18 51.43 
 
 
In this study the female patients were between the age group of 45 to 75 years. 
There were 3 (8.5%) patients in 45-55 years group. Youngest female patient in this 
study was 40 years old. 
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Chart 2: Age wise distribution of cases in Females 
 
 
 
Chart 2 shows the age wise distribution of cases in females. According to our study 
18 cases (51% of patients) were in the age group 65-75.  
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Chart 3: Comparison of Age wise distribution of cases in Males and Females  
 
 
 
Chart 3 shows the comparison of age in male and female cases with MI. Among 
male patients, the incidence of MI is more in age group 45-55yrs (42.86%) 
whereas in females, it is in 65-75 age group (51%). 
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SYMPTOMATOLOGY 
Typical symptoms of MI include substernal chest pain or pressure radiating to the 
arms and back associated with sweating, nausea, light headedness, palpitations.  
Other symptoms such as dyspnea, fatigue and lack of energy are considered as 
atypical symptoms and are found to be predominant in female patients in our 
study. 
 
Table 3: Symptoms at the time of admission in Male patients 
 
SL.NO SYMPTOMS NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  TYPICAL 26 74.29 
2.  ATYPICAL 9 25.7 
 
 
In the total of 35 male cases 74.29% (26 cases) had typical symptoms and 25.71% 
(9 cases) had atypical symptoms on presentation. 
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Chart 4: Symptoms at the time of admission in Male patients 
 
 
 
Chart 4 shows the number of cases having typical and atypical symptoms in male 
patients. According to our study male patients (74%) predominantly presented with 
typical symptoms. 
 
 
 
0
5
10
15
20
25
30
Typical Atypical
26
9
SYMPTOMS
76 
 
Table 4: Symptoms at the time of admission in Female patients 
 
SL.NO SYMPTOMS NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  TYPICAL 12 34.29 
2.  ATYPICAL 23 65.71 
 
 
Out of 35 female patients, 23 patients (65.71%) presented with atypical symptoms 
and only 12 cases (34.29%) had typical symptoms on presentation. 
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Chart 5: Symptoms at the time of admission in Female patients 
 
 
 
Chart 5 shows that 23 (65.71%) cases out of 35 cases had atypical symptoms and 
12 cases out of 35 (34.29%) cases presented with typical symptoms. 
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Chart 6: Comparison of Symptoms in Male and Female patients 
 
 
 
Chart 6 shows the comparative result of symptomatology at the time of admission 
in male and female patients. According to our study, typical symptoms are 
predominant in males while atypical symptoms are major presenting complaints in 
females.  
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Table 5: Menstrual status in Female patients 
 
SL.NO MENSTRUAL 
STATUS 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  MENSTRUATING 3 8.57 
2.  MENOPAUSAL 32 91.43 
 
 
In this study, out of 35 females, 32 patients (91.43%) were in post-menopausal 
status.  
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Chart 7: Menstrual status in Female patients 
 
 
 
Chart 7 depicts the menstrual status of female patients with CAD. According to our 
study 91% of patients were in post-menopausal status. 
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BMI  
Table 6: BMI Distribution in Male patients 
 
SL.NO BMI NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 21 60 
2.  OVER 
WEIGHT 
12 34.29 
3.  OBESE 2 5.71 
 
 
In the BMI evaluation of male patients, 60 % were found to be normal, 34.20 % 
cases were in over weight category and 5.71 % were in obese category.  
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Chart 8: BMI distribution in Male patients 
 
 
 
Chart 8 shows that 21 cases (60%) were Normal, 12 (34.20%) Overweight and 2 
(5.71%) obese. 
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Table 7: BMI distribution in Female patients 
 
SL.NO BMI NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 19 54.29 
2.  OVERWEIGHT 13 37.14 
3.  OBESE 3 8.57 
 
 
In the BMI Evaluation in 35 female cases, 19 cases were in Normal BMI category, 
13 cases were in over weight category, and 3 cases were in obese category. 
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Chart 9: BMI distribution in Female patients 
 
 
 
Chart 9 shows that in our study group, out of 35 females 19 (54.29%) were in 
normal, 13 (37.14%) were in overweight, and 3 (8.57%) were in obese category.  
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Chart 10: Comparison of BMI in Males and Female patients 
 
 
 
Chart 10 shows the comparative result of BMI in male and female patients of our 
study. During this evaluation of 70 cases. 40 cases (21 males and 19 females) were 
in normal BMI category, 25 cases (12 males and 13 females) were in over weight 
category, and 5 cases (2 males and 3 females) were in obese category. 
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LIPID PROFILE in Male and Female patients 
Total cholesterol > 200 mg%, LDL >100 mg% and HDL <40 mg% is considered 
as dyslipidaemia.  
 
Table 8: Total Cholesterol levels in Male patients  
 
SL.NO TOTAL 
CHOLESTEROL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 9 25.71 
2.  HIGH 26 74.29 
 
 
In the study 26 out of 35 male cases (74.29%) had High total cholesterol values 
and 9 out of 35 (25.71%) had normal cholesterol values. 
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Table 9: LDL levels in Male patients  
 
SL.NO LDL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 1 2.85 
2.  HIGH 34 97.14 
   
In our study 34 out of 35 male patients (97.14%) were having High LDL and only 
1 out of 35 (2.85%) had Normal LDL.  
Table 10: HDL levels in Male patients 
 
SL.NO HDL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1 NORMAL 19 54.28 
2 LOW 16 45.71 
 
In the study 19 out of 35 male cases (54.28%) had Normal HDL and 16 out of 35 
(45.71%) had low HDL.  
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CHART 11: Lipid Profile in Male patients 
 
 
 
Chart 11 displays the pattern of lipid profiles in male patients. 74.29% had High 
total cholesterol values, 97.14% were having High LDL and 45.71% had low 
HDL. 
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Table 11: Total Cholesterol levels in Female patients 
 
SL.NO TOTAL 
CHOLESTEROL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 8 22.85 
2.  HIGH 27 77.14 
 
 
In this study 27 out of 35 female cases (77.14%) were having High cholesterol and 
8 out of 35 (22.85%) were having normal cholesterol.  
 
Table 12: LDL levels in Female patients 
  
SL.NO LDL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1 NORMAL 7 20 
2 HIGH 28 80 
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In this study 28 out of 35 female cases (80%) were having High LDL and 7 out of 
35 (20%) were having Normal LDL.  
 
Table 13: HDL levels in Female patients 
 
SL.NO HDL 
LEVEL 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  NORMAL 14 40 
2.  LOW 21 60 
 
 
In this study 21 out of 35 female cases (60%) were having low HDL and 14 out of 
35 (40%) were having normal HDL.  
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Chart 12: Lipid Profile in Female patients 
 
 
 
Chart 12 displays the pattern of lipid profiles in female patients. 77.14% had High 
total cholesterol values, 80% were having High LDL and 60% had low HDL. 
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Table 14: ECG features of CAD in Male patients 
 
SL.NO ECG 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  STEMI 31 88.57 
2.  NSTEMI 4 11.43 
 
 
In this study, 31 cases out 35 cases in males (88.57%) had STEMI and 4 cases 
(11.43 %) had NSTEMI.  
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Chart 13: ECG features of CAD in Male patients 
 
 
 
Chart 13 shows the ECG features of CAD in male patients. According to our study 
STEMI is more common in male patients. 
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Table 15: ECG features of CAD in Female patients 
 
SL.NO ECG 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  STEMI 27 77.14 
2.  NSTEMI 8 22.86 
 
 
According to our study 77.14 % (27 out of 35 Females) had STEMI and 22.86 % 
(8 out of 35 females) had NSTEMI.  
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Chart 14: ECG features of CAD in Female patients 
 
 
 
Chart 14 shows the ECG features of CAD in female patients. According to our 
study STEMI is more common in female patients. 
 
0
5
10
15
20
25
30
STEMI NSTEMI
27
8
ECG COUNT
96 
 
Chart 15: Comparison of ECG features of CAD in Male and Female patients 
 
 
 
Chart 15 shows the comparison of ECG features between male and female patients. 
According to our study STEMI is the common presentation in both male and 
female patients and NSTEMI is more common in females than males.   
 
 
0
5
10
15
20
25
30
35
STEMI NSTEMI
31
4
27
8
MALE FEMALE
97 
 
Table 16: Type of MI in Male patients 
 
SL.NO WALL 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  AWMI 17 48.57 
2.  IWMI 4 11.43 
3.  ASMI 6 17.14 
4.  ALMI 2 5.71 
5.  IWMI/RVMI 6 17.14 
 
 
In this study of 35 male cases, 48.57% (17 out of 35) had AWMI, 17.14 % (6 out 
of 35) ASMI, 17.14 % (6 out of 35) IWMI/RVMI, 11.43 % (4 out of 35) IWMI 
and 5.71 % (2 out of 35) ALMI.  
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Chart 16: Type of MI in Male patients 
 
 
 
Chart 16 shows that in male patients AWMI is more common followed by ASMI 
and IWMI/RVMI  
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Table 17: Type of MI in Female patients 
 
SL.NO WALL 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  AWMI 18 51.43 
2.  IWMI 5 14.29 
3.  ASMI 9 25.71 
4.  ALMI 1 2.86 
5.  IWMI/RVMI 2 5.71 
 
 
In this study of 35 female cases 51.43% (18 out of 35) had AWMI, 25.71 % (9 out 
of 35) ASMI, 14.29 % (5 out of 35) IWMI and 5.71 % (2 out of 35) IWMI/RVMI 
and 2.86% (1 out of 35) ALMI. 
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Chart 17: Type of MI in Female patients 
 
 
 
Chart 17 shows that in female patients AWMI is more common followed by ASMI 
and IWMI  
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Chart 18: Comparison of Type of MI in Male and Female patients 
 
 
 
Chart 18 shows the comparison of type of MI between male and female patients. 
According to our study AWMI is the common presentation in both male and 
female patients, followed by ASMI. 
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Table 18: OUTCOME in Male patients 
 
SL.NO OUTCOME 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1 RECOVERY 33 94.29 
2 DEATH 2 5.71 
 
 
In this study of 35 male patients, 94.29 %( 33 out of 35) recovered and 5.71% (2 
out of 35) died.  
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Chart 19: OUTCOME in Male patients 
 
 
 
Chart 19 shows that in our study of 35 male patients with MI, 33 recovered with 
treatment while 2 patients died in spite of treatment. 
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Table 19: OUTCOME in Female patients 
 
SL.NO OUTCOME 
 
NO.OF CASES 
(n=35) 
PERCENTAGE 
% 
1.  RECOVERY 31 88.57 
2.  DEATH 4 11.43 
 
 
In this study of 35 female patients, 88.57 %( 31 out of 35) recovered and 11.43% 
(4 out of 35) died.  
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Chart 20: OUTCOME in Female patients 
 
 
 
Chart 20 shows that in our study of 35 female patients with MI, 31 recovered with 
treatment while 4 patients died in spite of treatment. 
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Chart 21: Comparison of OUTCOME in Male and Female patients 
 
 
 
Chart 21 shows the comparison of outcome in male and female patients. In our 
study of 70 cases with MI there were 6 deaths. Mortality is more in female patients 
than males. 
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PLASMA FIBRINOGEN ASSAY  
 
To find out the significance of plasma fibrinogen in coronary artery disease 
patients, plasma fibrinogen assay was done for 70 patients and entered into a 
master chart. 
 
Values between 150 – 400 mg/dl is considered as normal, value greater than 400 is 
considered as high. Data analysis was done using software called Epidemiological 
Information Package. 
 
Using this software, all the range, frequencies, percentage, mean, standard 
deviation, chi square and p value can be calculated. The tests used are One way 
ANOVA test and Student’s‘t’ test for data and Kruskul Wallis Chi-square test for 
consolidated tables. 
 
 ‘p’ value is calculated and value of less than 0.05 is considered significant.  
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Table 20: Plasma Fibrinogen levels in Male patients 
 
SL.NO FIBRINOGEN 
LEVEL 
 
NO.OF 
CASES 
(n=35) 
% 
IN 
MALE 
p 
VALUE 
ASSOCIATION 
1 NORMAL 4 11.42  
0.02 
 
Significant 2 HIGH 31 88.57 
 
 
In this study of 35 male patients with MI, 88.57 %( 31 out of 35) had high 
fibrinogen and 11.43% (4 out of 35) had normal fibrinogen. Here the calculated 
‘p’value is 0.02 which is <0.05 and hence the association is statistically significant.  
 
 
 
 
 
109 
 
Chart 22: Plasma Fibrinogen levels in Male patients 
 
 
 
Chart 22 depicts the level of plasma fibrinogen in male patients with CAD. 
According to our study 88.57 %( 31 out of 35) male patients had high fibrinogen 
levels and 11.43% (4 out of 35) male patients had normal fibrinogen levels. 
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Table 21: Plasma Fibrinogen levels in Female patients 
 
SL.NO FIBRINOGEN 
LEVEL 
 
NO.OF 
CASES 
(n=35) 
% 
IN 
FEMAL
E 
p 
VALUE 
ASSOCIATION 
1.  NORMAL 5 14.28  
0.001 
 
Significant 2.  HIGH 30 88.71 
 
 
In this study of 35 female patients with MI, 85.71 %( 30 out of 35) had high 
fibrinogen and 14.28% (5 out of 35) had normal fibrinogen. Here the calculated 
‘p’value is 0.001 which is <0.05 and hence the association is statistically 
significant. 
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 Chart 23: Plasma Fibrinogen levels in Female patients 
 
 
 
Chart 23 depicts the level of plasma fibrinogen in female patients with CAD. 
According to our study 85.71 %( 30 out of 35) female patients had high fibrinogen 
levels and 14.28% (5 out of 35) female patients had normal fibrinogen levels. 
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Table 22: Comparison of Plasma Fibrinogen levels in Male and Female 
patients 
 
SL.NO FIBRINOGEN 
LEVEL 
 
MALE FEMALE % 
IN 
MALE 
% 
IN 
FEMALE 
p 
VALUE 
IN 
MALE 
p 
VALUE 
IN 
FEMALE 
1 NORMAL 4 5 11.42 14.28        
0.02 
      0.001 
2 HIGH 31 30 88.57 85.71 
 
 
In our  study of 70 patients with CAD (35males and 35 females), it was found that 
88.57% (31 out of 35) of male patients had high fibrinogen and 85.71% (30 out of 
35) of females had high fibrinogen. 
The p value for male patients is 0.02, and for female patients is 0.001, both of 
which are less than 0.05, and hence the association is statistically significant. 
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Chart 24: Comparison of Plasma Fibrinogen levels in Male and Female 
patients 
 
 
 
Chart 24 shows the comparative study of plasma fibrinogen levels in male and 
female patients with CAD. According to our study 88.57% (31 out of 35) of male 
patients had high fibrinogen and 85.71% (30 out of 35) of females had high 
fibrinogen. 
0
5
10
15
20
25
30
35
NORMAL FIBRINOGEN HIGH FIBRINOGEN
4
31
5
30
MALE FEMALE
114 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
115 
 
DISCUSSION 
 
Coronary artery disease (CAD) is the leading cause of death in developed countries 
and is rapidly becoming one in developing countries. For a long time, coronary 
artery disease (CAD) was considered as a disease of men and women were not 
included in the studies. In developing countries, CVD causes half of all deaths of 
women over 50 years of age and third of all deaths of women, worldwide. Also, 
women form a distinct subgroup within the patients with CAD because of 
differences between women and men with respect to prevalence, presentation, 
management and outcomes of the disease. 
 
Also, traditional risk factors cannot explain all cases of CAD in our Indian 
population. The increased incidence of CAD in the young suggests the possibility 
of non-conventional risk factors.  
 
In recent times, the role of plasma fibrinogen as an independent cardiovascular risk 
factor has been increasingly appreciated .Elevated plasma fibrinogen levels may 
reflect a prothrombotic or hypercoagulable state, as it is a major determinant of 
fibrin formation, blood viscosity and platelet aggregation. This increases the 
thrombogenic tendency and may lead to the development of atheromatous lesion in 
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CAD and may also cause the ruptured atheromatous plaques to occlude the lumen 
in patients with coronary artery disease. 
 
But very few studies are available to establish the relationship between plasma 
fibrinogen and coronary artery disease in women.Hence this study was undertaken 
to evaluate the role of plasma fibrinogen as a determinant for CAD in women. 
 
Seventy patients including both male and females admitted to coronary care unit 
with evidence of acute myocardial infarction features in electrocardiogram were 
randomly selected and data collected with the follow up during the hospital stay of 
patients. Plasma fibrinogen level were measured in all the patients.  
 
Diabetes mellitus is an important confounder in the relationship between plasma 
fibrinogen and CAD. Another potential confounder is smoking. So patients with 
diabetes and smokers were excluded from this study. This was done to ensure that 
the effect of plasma fibrinogen on cardiovascular risk is not simply the result of 
cigarette smoking or diabetes mellitus. Thus, we provide evidence that plasma 
fibrinogen is associated with increased risk of female CAD, independent of 
potentially confounding cardiovascular risk factors. Also, women on HRT, OCP, 
and drugs that affects fibrinogen levels were excluded from this study.  
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 In this study the average age of males were 56.05 and average age of 
females were 64.17. Among male patients, the incidence of MI is more in 
age group 45-55yrs (42.86%) whereas in females, it is in 65-75 age group 
(51%). 
Women of advanced age develop more complications and mortality. 
Johanne Neil et al state that the excess mortality in women is due to olderage  
of presentation in women   
 
 
 Women having an MI are more likely to present with atypical chest pain 
(midback pain) and atypical symptoms (indigestion, nausea, vomiting and 
dyspnea). 
 In the FHS, among women with typical angina,only 17% developed MI 
while 44% of men with angina developed MI  
In the Coronary Artery Surgery Study (CASS), 83% of men with typical 
angina had significant CAD while only 50% of women with typical angina 
had significant CAD 
 
In our study 25.71% of male patients had atypical symptoms on 
presentation, while 65.71% of female patients presented with atypical 
symptoms.  
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 Unique to women is the influence of their hormonal status on CAD. In 
comparison with men of a similar age and postmenopausal women, the 
incidence of CAD is significantly lower in premenopausal women 
suggesting that endogenous estrogens have a protective effect on the 
development of CAD.  
In our study 91.43% of female patients were in post-menopausal status. 
 
 The annual prevalence of obesity among U.S. adults age 20 and older has 
increased from 19.4% in 1997 to 23.9% in 2002 (Centers for Disease 
Control and Prevention, 2003). For the first six months of 2003, the 
prevalence of obesity among women was highest among non-Hispanic black 
women (38.7%), followed by Hispanic or Latino women (25.7%). 
During this evaluation of 70 cases. 40 cases (21 males and 19 females) were 
in normal BMI category, 25 cases (12 males and 13 females) were in over 
weight category, and 5 cases (2 males and 3 females) were in obese 
category. 
The JAIPUR HEART WATCH (JHW) studies reported that there is a 
significant increase in total cholesterol, LDL cholesterol and triglycerides 
and a decline in HDL cholesterol is women and men at all age groups.  
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In our study, among male patients. 74.29% had High total cholesterol values, 
97.14% were having High LDL and 45.71% had low HDL. Among female 
patients. 77.14% had High total cholesterol values, 80% were having High 
LDL and 60% had low HDL.  
 
 According to our study STEMI is the common presentation in both male 
(88.57%) and female (77.14 %) patients and NSTEMI is more common in 
females (22.86 %) than males (11.43 %).  
 
 According to our study the most common pattern of presentation in both 
male and female patients is Anterior Wall Myocardial Infarction, followed 
by Anteroseptal Wall Myocardial Infarction. 
 
 
 
  In our study of 70 cases with MI there were 6 deaths. Mortality is more 
common in female patients than males. This is because women classically 
present at an advanced age, with atypical symptoms resulting in a delay of 
initiation of treatment or inadequate treatment leading to poor short term 
outcome. There is a significant delay in reaching the treatment care center.  
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Sandra et al state that, women receive somewhat less aggressive treatment 
during the early management of acute myocardial infarction. 
 Hani Jneid et al state that the under use of evidence based treatments and 
delayed reperfusion among women represent potential opportunities for 
reducing poor outcomes after AMI. 
 
 
 In our  study of 70 patients with CAD (35males and 35 females), it was 
found that 88.57% (31 out of 35) of male patients had high fibrinogen and 
85.71% (30 out of 35) of females had high fibrinogen.  
The p value for male patients is 0.02, and for female patients is 0.001, both 
of which are less than 0.05, and hence the association is statistically 
significant.  
 
In the Atherosclerosis Risk in Communities (ARIC) Study, a large, 
population-based, prospective study, plasma fibrinogen was found to be an 
important risk factor for CAD in women. Elevated plasma fibrinogen was 
also associated with all-cause mortality in this population.  
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The Scottish Heart Health Study, a random population sample with a follow-
up period of ≈8 years, recently reported plasma fibrinogen to be a risk factor 
for CAD mortality and all-cause mortality in women.  
In a Finnish population-based, case-control study, women with prevalent 
CAD had higher plasma fibrinogen concentrations than with women free of 
disease.  
 
Our study is a cross sectional observational study. So it has its own limitations. 
Cross sectional studies are susceptible to several sources of bias and confounding. 
There may be many shortcomings in this study. But this study will definitely give 
us a fair idea about the association of plasma fibrinogen with CAD in female 
patients. 
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SUMMARY 
 
In our study of 70 patients (35 male, 35 female) with acute myocardial 
infarction. It   was found that  
 
 Among male patients, the incidence of MI is more in age group 45-55yrs 
(42.86%) whereas in females, it is in 65-75 age group (51%). 
 
 Typical symptoms are predominant in males while atypical symptoms are 
major presenting complaints in females. 
 
 
 Majority of female (91%) patients were in post-menopausal status. 
 
 STEMI is the common presentation in both male and female patients and 
NSTEMI is more common in females than males. 
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 Anterior Wall Myocardial Infarction is the common presentation in both 
male and female patients, followed by Anteroseptal Wall Myocardial 
Infarction. 
 
 Mortality is more in female patients than males. 
 
 
 Plasma fibrinogen was high in both male (Mean 424.59) and female (Mean 
427.97) patients and association was statistically significant.  
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CONCLUSION 
 
Coronary Artery Disease continues to take a heavy toll on the Indian population. 
But not all cases of CAD can be explained by conventional risk factors. Hence the 
search for novel risk factors is warranted to reduce the cardio vascular disease 
burden in the community. 
 
The role of plasma fibrinogen as an independent cardio vascular risk factor has 
been increasingly recognized in recent years. But the association between plasma 
fibrinogen and cardiovascular risk does not establish a cause-effect relation, 
because plasma fibrinogen levels are related to several major lifestyle and physical 
characteristics known to be associated with increased risk of CAD.  
 
But more research is still needed to find out the value of measuring plasma 
fibrinogen levels in clinical practice and identifying 'high fibrinogen' genotypes in 
cardiovascular health screening. However, routine measurement of plasma 
fibrinogen levels has to take into account the influence of age, sex, smoking and 
other disease states (like renal and liver impairment) on the measured levels in the 
individuals screened.  
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At present, there are limited therapeutic strategies for reducing plasma fibrinogen. 
Therefore routine clinical measurement of this marker may be of limited value. In 
addition, an internationally accepted standardised procedure for measurement of 
plasma fibrinogen, and the initiation long-term prospective studies (especially into 
effects of reducing high plasma fibrinogen levels) are needed. A full understanding 
of the role of plasma fibrinogen in cardiovascular disorders is still required in 
elucidating the molecular biology of atherogenesis and thrombogenesis. 
 
LIMITATIONS: 
Our study has some limitations.  
 Although other chronic conditions that may influence fibrinogen synthesis 
were excluded, the possibility that the observed elevated fibrinogen was a 
result, rather than a cause of atherosclerosis, cannot be ruled out.  
 
 Since the majority of individuals enrolled were dyslipidemic, the results are 
mainly valid for this specific vascular risk subgroup.  
 
 
 In this study, we tried to adjust for some but not all the possible 
confounders. It is known that other genetic, metabolic and environmental 
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factors not included in the present analysis could influence the fibrinogen 
levels. 
 
 Finally, the sample size means that the results cannot automatically be 
extended to other populations at risk for CAD. 
 
In conclusion, the findings from our study provide evidence that plasma fibrinogen 
is associated with excess risk of CAD in women. It seems likely that high plasma 
fibrinogen levels, whatever their origins, contribute substantially to the risk of 
coronary thrombotic events in women. Further large scale studies are needed to 
establish the causal relationship of fibrinogen to coronary artery disease in both the 
sexes. 
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ANNEXURE - 1 
 
PROFORMA 
 
SERIAL NUMBER:    
 
NAME:                                                                 
 
AGE:     
 
SEX:  
 
IP.NO:                               
 
Date of Admission:                            
 
Date of Discharge: 
 
CHIEF COMPLAINTS: 
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HISTORY OF PRESENTING ILLNESS:   
 
 
CHEST PAIN 
 
SWEATING 
 
DYSPNEA 
 
VOMITING 
 
PALPITATION 
     
   
 
PAST HISTORY:  
 
 
DM 
 
 YES          NO 
 
SHT 
 
 YES          NO 
 
CAD 
 
 YES          NO 
 
RHD/CHD 
 
 YES          NO 
 
CVA 
 
 YES          NO 
 
PVD 
 
 YES          NO 
 
LIVER/RENAL FAILURE 
 
 YES          NO 
 
144 
 
PERSONAL HISTORY:   
  
 
DIET 
             
            VEG          NONVEG 
 
TOBACCO 
 
           SMOKE     CHEW 
           NO                                         
 
ALCOHOLIC 
 
          YES            NO 
 
 
MENSTRUAL HISTORY [For Female Patients Only]:  
 
 
MENOPAUSAL 
 
     PRE          POST 
 
 
DRUG HISTORY:       
 
 
OCP/HRT 
 
OTHERS 
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GENERAL EXAMINATION: 
 
 
BMI 
HT: 
WT: 
 
 
VITALS 
PR: 
BP: 
RR: 
 
 
SYSTEM EXAMINATION: 
 
 
CVS 
 
 
RS  
P/A  
CNS  
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INVESTIGATIONS: 
CBC 
  
RBS 
  
RFT 
  
LFT 
  
LIPID PROFILE 
  
CPK-MB 
TROPONIN-T 
PLASMA FIBRINOGEN 
  
ECG  
 
CXR 
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TREATMENT: 
 
 
OUTCOME:  
 
 
Outcome 
 
 RECOVERY          DEATH 
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ANNEXURE – 2 
 
PATIENT CONSENT FORM 
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ANNEXURE - 3 
MASTER CHART 
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ANNEXURE - 4 
KEY TO MASTER CHART 
  
BMI Body Mass Index 
TC Total Cholesterol 
LDL Low Density Lipo Protein 
TGL Triglyceride 
HDL High Density Lipo Protein 
CPK-MB Creatinine Phospo Kinase – MB 
STEMI ST Elevation Myocardial Infarction 
NSTEMI Non ST Elevation Myocardial Infarction 
AWMI Anterior Wall Myocardial Infarction 
IWMI Inferior Wall Myocardial Infarction 
ASMI Antero Septal Myocardial Infarction 
ALMI Antero Lateral Myocardial Infarction 
RVMI Right Ventricle Myocardial Infarction 
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ANNEXURE - 5 
LIST OF ABBREVIATIONS 
ACC - American college of cardiology 
ACS - Acute coronary syndrome 
AHA - American heart association 
ASMI - Antero septal myocardial infarction 
AWMI - Anterior wall myocardial infarction 
BMI - Body mass index 
BP - Blood pressure 
CAD - Coronary artery disease 
CHD-Congenital Heart Disease 
CPK – MB – Creatine Phospho Kinase - MB 
CVA-Cerebrovascular Accident  
CVD - Cardio vascular disease 
CXR –Chest X Ray 
DM- Diabetes Mellitus 
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ECG - Electrocardiogram 
HDL - High density lipoprotein 
HLMI - High lateral myocardial infarction 
HRT-Hormone Replacement Therapy   
ICAM-Intracellular adhesion molecule-1 
IHD - Ischemic heart disease 
INR - International normalized ratio 
IWMI - Inferior wall myocardial infarction 
JNC-Joint National Committee 
LDL - Low density lipoprotein 
MI - Myocardial infarction 
NCEP-National Cholesterol Education Programme 
OCP- Oral Contraceptive Pills 
PCI - Percutaneous coronary intervention 
PVD-Peripheral vascular disease 
PWMI - Posterior wall myocardial infarction 
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RHD-Rheumatic Heart Disease 
RVMI - Right ventricular myocardial infarction 
RWMA - Regional wall motion abnormality 
SHT-Systemic Hyper Tension 
STEMI - ST elevation MI 
UA - Unstable angina 
WHO-World Health Organization 
